Quick Answer
Royalty Pharma plc reported Total Revenue of $2.38 billion for the year ending 2025.
- Royalty Pharma plc showed an increase of +5.1% in Total Revenue from 2024 to 2025.
- This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $457.61 million | Q3 2019: $464.28 million | Q1 2020: $500.88 million | Q2 2020: $510.93 million | Q3 2020: $538.40 million | Q1 2021: $573.03 million | Q2 2021: $554.96 million | Q3 2021: $585.77 million | Q1 2022: $562.05 million | Q2 2022: $535.96 million | Q3 2022: $573.46 million | Q1 2023: $683.97 million | Q2 2023: $538.20 million | Q3 2023: $536.31 million | Q1 2024: $567.98 million | Q2 2024: $537.27 million | Q3 2024: $564.69 million | Q1 2025: $568.25 million | Q2 2025: $578.67 million | Q3 2025: $609.29 million.
- Over the full 8 years of available data (2018 to 2025), Royalty Pharma plc's Total Revenue has grown by 32.5%.
- Historical annual values: Fiscal year 2025: $2.38 billion | Fiscal year 2024: $2.26 billion | Fiscal year 2023: $2.35 billion | Fiscal year 2022: $2.24 billion | Fiscal year 2021: $2.29 billion | Fiscal year 2020: $2.12 billion | Fiscal year 2019: $1.81 billion | Fiscal year 2018: $1.79 billion.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: